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Effects of angiotensin II on plasma antidiuretic hormone and renal
water excretion. The effects of intravenous (i.v.) and intracarotid (IC)
angiotensin II (All) infusion on systemic and renal hemodynamics,
renal water excretion, and plasma antidiuretic hormone (ADH) levels
were examined in six conscious dogs under water loaded and
hydropenic conditions. In the first group of seven studies, All in a mean
dose of 12.7 ng/kg/min was administered Lv. to water loaded dogs. The
infusion induced a significant increase in mean arterial pressure (MAP,
99 to 118 mm Hg, P < 0.001), and significant reductions in both
glomerular filtration rate (GFR, 67 to 57 mI/mm, P < 0.05) and
para-aminohippurate clearance (cPAH, 280 to 212 mI/mm, P < 0.005)
occurred. Despite this decrement in renal hemodynamics, urine re-
mained maximally dilute (Uosm, 58 to 61 mOsm/kg H,O, NS). Further-
more, plasma ADH was suppressed maximally after water load and did
not increase after iv. All infusion. The IC infusion of All (mean dose
5.8 ng/kg/min) produced similar changes in hemodynamics; plasma
ADH remained undetectable. When All was administered iv. to
hydropenic animals (mean dose 8.3 ng/kg/min), MAP again increased
(86 to 111 mm Hg, P < 0.001) as GFR (81.3 to 68.6 mi/mm, NS) and
CPAH (291 to 223 mI/mm, P < 0.05) declined modestly. In these
animals, Uosm decreased significantly (1429 to 1114 mOsm/kg H20, P
< 0.005) and plasma ADH did not change significantly (1.66 to 1.88
pglml, NS). When IC All (4 ng/kg/min) was repeated in hydropenic
dogs pretreated with indomethacin, neither Usom (1787 to 1664
mOsm/kg H20, NS) nor plasma ADH were altered. In summary, these
results provide no evidence for an effect of All to alter water excretion
or plasma ADH either in the presence or absence of prostaglandmn
inhibition.
In recent years there has been an increased focus upon an
understanding of the factors involved in the regulation of
vasopressin release and renal water excretion [11. In spite of
these advances, the precise interrelationship between the
renin—angiotensin system and renal water excretion remains an
area of continued controversy. Some investigators have pro-
vided support for the concept that circulating angiotensin II
(All) is an important stimulus to vasopressin release [2—41 in the
dog, while others have failed to observe a stimulation of either
baseline or nonosmotically stimulated vasopressin release
[5—71.
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In man similar conflicting findings have resulted, with Uhlich
et al suggesting that All stimulates vasopressin release [8],
while Davies, Forsling and Slater found little support for a
physiological role of All in regulating vasopressin release [91.
While several studies in vivo [10, 111 and in vitro [12, 131 have
suggested that All may directly stimulate vasopressin release
from the rat hypothalamoneurohypophyseal system, Ruoff,
Gosbee and Lederis have found that All applied to the neural
lobe in vitro or in vivo inhibits vasopressin release [4]. The
physiologic significance of these latter studies is unclear, since
the existence of a brain renin—angiotensin system is still debat-
able [14].
In view of the controversy in this area in research, we
attempted to further investigate the potential relationship be-
tween the renin—angiotensin system and vasopressin release.
The experimental protocol incorporated the following features:
1) All studies were performed in trained conscious dogs to
eliminate the influence of anesthesia; 2) A sensitive radio-
immunoassay for vasopressin was employed to avoid a lack of
sensitivity or specificity of the bioassay for vasopressin; 3) Both
intracarotid (IC) and intravenous (i.v.) infusions were per-
formed; 4) Studies were performed in water—diuresing animals
to examine the end—organ renal response to any angioten-
sin—stimulated release of vasopressin; 5) Studies were per-
formed in fluid—deprived animals to examine whether angioten-
sin augmented osmotically—stimulated vasopressin release; 6)
Studies were performed in animals after inhibition of
prostaglandin (PG) synthesis to examine whether vasopres-
sin—stimulated renal PG might impair the end—organ response to
angiotensin—stimulated release of vasopressin. The results of
these studies provide no evidence for an important role for the
renin—angiotensin system in either vasopressin release or renal
water excretion in the conscious dog.
Methods
Studies were performed on seven trained, conscious female
dogs weighing between 20 and 30 kg. All animals had one
carotid artery surgically exteriorized through a subcutaneous
tunnel at least one month prior to the experiments. Each animal
underwent at least one month of training prior to the beginning
of these studies; during this time the dogs were trained to lie
quietly for several hours with all experimental catheters in
place. Each of the dogs remained completely restful and unagi-
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tated during these experiments, all of which were performed in
a quiet room. The dogs were fed a normal diet consisting of
approximately 60 mEq of sodium and 50 mEq of potassium
daily. Water was offered ad libitum and food was withheld the
morning of the study. All studies were performed with the dogs
fully conscious.
On the day of each study a urethral catheter was inserted for
collection of urine. A polyethylene catheter was placed
percutaneously via an external jugular vein into the right
atrium. A third short polyethylene catheter was inserted
percutaneously into the exteriorized carotid artery for blood
pressure measurement. After these catheters were inserted, the
dogs lay quietly on their sides in a quiet room for 30 to 40
minutes prior to the beginning of the experiment. Isotonic saline
(0.5 mI/mm) containing a concentration of sufficient inulin (4
g%) and para aminohippurate (PAH) (0.6 g%) for clearance
measurements was begun 45 minutes to one hour prior to the
collection of urine and blood. Cardiac ouputs were performed
by the indicator—dilution principle with indocyanine green dye
(cardio-green) as the indicator [15].
In those animals (Groups 1, 2A, and 2B) which received a
water load prior to the All infusion, 20 mI/kg of 2.5% dextrose
and water solution was evenly infused intravenously over a
period of one hour. All animals receiving the water load had a
urinary osmolality (Uosm) of less than 100 mOsm/kg H20 prior
to the beginning of the study. In the hydropenic studies (Groups
3 and 4), water was withheld from the animals for a period of 18
to 22 hours prior to the study.
Mean arterial pressure and pulse were recorded on a Gilson
multichannel recorder with a Statham transducer. All was
obtained from Ciba—Geigy, LTD. (Basel, Switzerland).
After equilibration of the inulin and para-aminohippurate
(PAH) infusions, a series of control clearance periods were
performed, consisting of two or three 10 minute collections of
urine. Blood samples for PAH, inulin, and arginine vasopressin
(AVP) determination were drawn at the midpoint of each
clearance period. Heart rate and blood pressure were measured
prior to blood collection. At the conclusion of the control
period, an isotonic solution containing different concentrations
of All was begun either via i.v or IC routes. Following five to 10
minutes of infusion, two or three additional 10 minute clearance
periods were performed. The total time of the All infusion
averaged 40 minutes, and the experimental AVP samples were
drawn at 15 and 25 to 35 minutes after the start of All.
Clearance calculations were performed as previously described
[16]. The animals were subjected to four experimental condi-
tions listed below. Although each animal was studied under
more than one protocol, at least two weeks' time separated the
studies in any one animal.
Group 1 (7 studies). Water loaded animals received All in a
mean dose of 12.7 ng/kg/min (range 8 to 20 ng/kg/min). The dose
of All infused in this and subsequent groups was individually
selected so that systemic blood pressure did not increase by
more than 25 mm Hg in any dog.
Group 2A (6 studies). Water loaded animals received All IC
in a mean dose of 5.8 ng/kg/min.
Group 2B (5 studies). A higher dose of All i.v. (20 ng/kg/min)
was given to water loaded animals.
Group 3 (7 studies). Animals were fluid deprived for 18 to 22
hours and received All i.v. at a mean dose of 8.3 ng/kg/min
(range 5 to 10 ng/kg/min).
Group 4 (5 studies). Hydropenic animals pretreated with
indomethacin received All IC in a mean dose of 4 ng/kg/min
(range 3 to 8 nglkg/min). The indomethacin dose was 2.5
mg/kg/day by mouth for two days prior to the study followed by
an i.v. bolus of 2 mg/kg of indomethacin 60 minutes prior to
study. The dose of indomethacin has been previously associ-
ated with tissue PG depletion in rats [17] and reduced urinary
PGE2 excretion from 740 pg/mm to 151 pg/mm (P < 0.005) in
four dog studies performed in our laboratory.
Analytical methods
Plasma AVP was measured by radioimmunoassay using
methodology previously described [18] and samples were ana-
lyzed in a blind manner. The recovery of this method is
79.3 4.4%. The interassay coefficient of variation is 6.0% at
AVP concentrations of 2.6 pg/mI. The lower limit of detect-
ability for this assay is 0.5 pg/mI [181. The response of AVP
concentrations to an increasing plasma osmolality has been
tested in our laboratory [19]. The osmotic threshold is consist-
ant in any given animal but varies between 288 and 296
mOsm/kg H20. The plateau for AVP concentrations stimulated
with an osmotic challenge is between 1.5 and 1.8 pg/ml and is
reached after plasma osmolality increases between 4 and 8
mOsm/kg H20. Plasma renin activity (PRA) was determined by
radioimmunoassay as described previously [20].
Analysis of blood for inulin and PAH was performed as
previously described [16]. Urinary and plasma osmolality was
measured cryoscopically by freezing point depression on an
Advanced Instruments osmometer (model 3L).
Statistics on paired clearance and hemodynamic data were
performed by employing Student's 1-test after results of control
and experimental periods were averaged. AVP values were
analyzed by comparing the mean of the control values with the
two experimental values by Duncan's method of multiple
comparisons. Statistical significance was defined as P < 0.05
and the results are expressed as the mean one standard error of
the mean.
Results
Effect 0! Al! on systemic and renal heinodynamics (Table 1)
The infusion of All induced a significant increase in mean
arterial pressure in all five groups of animals. The effects of All
on cardiac output and heart rate were less consistent, however,
as no statistically significant alterations were observed with All
infusion.
Glomerular filtration rate (GFR) and PAH clearance declined
significantly with All infusion in Group I studies. A moderate
hut statistically insignificant decline in GFR was observed in the
other Groups; the decline in PAH clearance reached statistical
significance in Groups 1, 2A and 3. In the animals rendered
hydropenic and pre-treated with indomethacin (Group 4),
preinfusion GFR and PAH clearances were depressed and GFR
was moderately, but not significantly, increased with All infu-
sion.
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Table 1. Effect of All on systemic and renal hemodynamicsa
MAP CO HR GFR CPAH
mm Hg liter/mm beats/mm mI/mm mI/mm
C All C All C All C All C All
Or I (N = 7)h
Mean 99 118 5.7 5.4 119 124 67 57 280 212
SE 3.3 4.9 0.5 0.4 8 9 3.5 3.4 12 12
P <0.001 NS NS <0.05 <0.005
Gr 2A: (N = 6)
Mean 100 112 5.0 5.2 116 110 72 68 262 228
SE 3.6 5.0 0.6 0.9 12 12 4 3 4.5 7.4
P <0.005 NS NS NS <0.025
Or 2B: (N = 5)
Mean 90 120 3.6 3.0 83 71 51 34 228 119
SE 4.4 4.6 0.4 0.5 9 8 5.2 10.4 26 48
P <0.001 NS NS NS NS
Gr 3: (N = 7)
Mean 86 III 4.0 3.8 92 92 81 69 291 223
SE 3 3 0.6 0.6 12 10 13 9 48 40
P <0.001 NS NS NS <0.05
Gr 4: (N = 5)
Mean 93 109 3.6 3.7 93 86 37 55 120 158
SE 3.9 4.3 0.6 0.9 8.9 8.6 3.7 15.9 15 43
P <0.005 NS NS NS NS
a Abbreviations are C, control; All, angiotensin II; MAP, mean arterial pressure; CO, cardiac output; HR, heart rate; GFR, glomerular filtration
rate; CPAH, paraaminohippurate clearance.
Gr 1: i.v. hydrated; Gr 2A: IC hydrated; Or 2B: i.v. hydrated; Gr 3: i.v. hydrated; Gr 4: IC dehydrated.
Table 2. Effect of All on renal water excretion and plasma AVPU
AVP
(pg/mi)
pOsm Uosm Cu() All All(mOsm/kg H20) (mOsm/kg H20) (mi/mm) (mOsm/min) 5—35
C All C All C All C All C mm mm
Gr 1: (N = 7)
Mean 284 285 58 61 5.7 5.4 1.53 1.22 <0.5 <0.5 <0.5
SE 5 6 3.4 5.0 0.5 0.4 0.14 0.11
P value NS NS NS NS NS NS
Gr 2A: (N = 6)
Mean 292 291 58 85 5.5 4.6 1.68 1.61 <0.5 <0.5 <0.5
SE 6 6 5.6 3.4 0.2 0.9 0.19 0.2
P value NS NS NS NS NS NS
Gr 2B: (N = 5)
Mean 287 286 82 138 4.06 0.73 1.56 0.62 <0.5 <0.5 <0.5
SE 4 4 10 21 0.50 0.30 0.10 0.18
P NS <0.05 <0.01 <0.01 NS NS
Gr 3: (N = 7)
Mean 303 304 1429 1114 —1.13 —0.81 1.65 1.27 1.67 1.91 1.88
SE 7 5 265 231 0.18 0.18 0.17 0.18 0.66 0.63 0.46
P value NS <0.005 NS NS NS NS
Gr 4: (N = 5)
Mean 324 319 1787 1664 —0.99 —1.08 1.23 1.37 0.93 1.01 1.23
SE 9 10 282 247 0.15 0.28 0.15 0.37 0.37 0.53 0.75
P value NS NS NS NS NS NS
a Abbreviations are: pOsm, plasma osmolality; U,,,, urinary osmolality; CHO, clearance of water; C,m, osmolar clearance; AVP, Plasma AVP.
Other abbreviations as in Table 1.
Effrct of All on renal water excretion, plasma AVP, and be initially low and any stimulatory effect of All on AVP and
PRA (Table 2) Uosm would be readily appreciated. As shown in Table 2,
neither Uosm (58 to 61 mOsm/kg H20, NS) nor free water
Studies in Groups I and 2 were performed in the animals after clearance (cH20, 5.7 to 5.4 mI/mm, NS) were significantly
a 20 mI/kg i.v. water load SO that Uosm and plasma AVP would altered by All iv. infusion at a dose of 12.7 ng/kg/min. Plasma
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AVP values remained in the undetectable range (<0.5 pg/mI)
either 15 or 25 to 35 minutes after the start of All infusion. In
three of the dogs with a low pressor response (<100mm Hg) to
Al!, neither AVP nor Uosm were altered by the infusion.
In order to test whether IC administration of AlT stimulated
AVP release, studies were performed in which IC All (5.8
ng/kg/min) was administered after the water load (Group 2A).
These infusions again failed to result in any change in Ijosm (58
to 85 mOsm/kg H20, NS). CH2O did not fall significantly (5.5 to
4.6 mI/mm, NS) and plasma AVP remained in the undetectable
range during All infusion. In the five dogs (Group 2B) with the
highest dose of i.v. All (20 ng/kg/min), the most dramatic
decline in the renal hemodynamics was observed. Urinary
osmolality increased moderately but significantly (82 to 138
mOsm/kg H,O, P < 0.02) in this group; however, plasma AVP
levels remained undetectable.
Earlier experiments by Shimizu, Share and Claybaugh [211
had suggested that an increased plasma osmolality was neces-
sary for the demonstration of an effect of All to stimulate AVP
release. Thus, the animals were denied water for 18 to 22 hours
prior to the study (Group 3), a maneuver which significantly
increased plasma osmolality (284 to 303 mOsm/kg H20, P <
0.001). All infusion in these hydropenic animals was actually
associated with a decrease in Uosm (1429 to 1114 mOsm/kg
H20, P < 0.005) without a detectable change in plasma AVP
levels (1.67 control to 1.91 and 1.88 pg/mi after 15 and 25 to 35
minutes of All infusion, respectively).
The ability of renal PG to influence the effects of Al! on water
excretion was assessed in the final group of studies (Group 4).
The animals were dehydrated as in the Group 3 studies (plasma
osmolality 320 mOsm/kg H20) but were also given oral indo-
methacin for two days prior to the study as well as an i.v. bolus
of 2 mg/kg one hour before All infusion. Renal PGs are known
to be increased by All [22, 23] and are in vivo antagonists to the
hydroosmotic effects of ADH [17]. Thus, renal PGs could
conceivably mask or blunt any increase in urine concentration
associated with AT! mediated increases in AVP. Inhibition of
PG synthesis followed by All infusion did not, however, result
in either a significant increase in Uosm (1787 to 1664 mOsm/kg
H,O, NS) or a significant decrease in cH20 (—0.99 to —1.08
mi/mm, NS). Plasma AVP again failed to change with the All
infusion in these Group 4 studies (0.93 control to 1.01 and 1.23
pg/mi after All infusion, NS).
Baseline (pre-All) PRA was 1 .43 0.2 ng/ml/hr in water
loaded dogs; following the All infusions, PRA declined to 0.98
0.11 ng/ml/hr, a statistically insignificant decline. In the
hydropenic dogs, baseline PRA was 1.17 0.18 ng/ml/hr; All
had no significant effect on PRA as the post-infusion value was
1.32 0.15 ng/ml/hr.
Discussion
The hypothesis that the renin—angiotensin system might
affect not only sodium excretion by stimulating aldosterone
release but also water excretion by stimulating AVP is attrac-
tive. Conclusive evidence in support of this hypothesis, how-
ever, has been difficult to obtain. After observations of Bonjour
and Malvin [2] indicating a rise in bioassay titers of AVP during
i.v. and IC infusions of All in the anesthetized dog, other
groups have failed to provide support for this hypothesis [7, 241.
Moreover, stimulation of the renin—angiotensin system has
been dissociated from the stimulation of AVP during
hypotensive maneuvers in both dog [6, 211 and man [24].
Recent studies by Claybaugh [25] and Ramsay et al [3],
however, have rekindled interest in the possibility that the
renin—angiotensin system may be an important modulator of
AVP release. The latter study was of particular importance
since the studies were performed in conscious animals using a
radioimmunoassay for AVP [3]. However, changes in renal
water excretion were not- presented in these studies, and one
cannot determine whether increases in radioimmunoassayable
AVP were accompanied by concomitant changes in urine
concentration and water excretion. The data would have lent
added support to the hypothesis that angiotensin—mediated
AVP release is of physiologic importance. Although a pressor
effect would normally suppress baroreceptor—mediated AVP
release, as has been shown with norepinephrine [261, it is
possible that the paradoxical effect of angiotensin to raise AVP
levels might be due to a nonspecific stress, such as agitation or
nausea, in these previous studies. This possibility was not
controlled in the study of Ramsay et al by using a pressor agent
other than All [31.
A similar result linking angiotensin to an increase in plasma
AVP values was recently reported by Usherti et al [27]. In these
studies, pressor doses of All given to humans (5 to 13
ng/kg/min) raised AVP moderately, hut significantly, and low-
ered urinary osmolality. The use of aspirin in this group resulted
in a decline in free—water clearance. The results were inter-
preted to show a significant stimulation of AVP by angiotensin
II. However, no control pressor infusion (non All infusion) was
employed in these studies, and the changes in urinary osmolal-
ity and plasma AVP were not large. Other studies in humans
using several stimuli to AVP release have not been positive [9,
28, 29].
In the present investigation, conscious animals were studied
during both i.v. (Group I) and IC (Group 2A) infusion of All.
The initial studies were performed in water loaded animals with
maximally suppressed levels of AVP (<0.5 pg/mI) and maxi-
mally dilute urines (Uosm <100 mOsrn/kg H20). These water
diuresing animals thus provided an in vivo bioassay to docu-
ment that any increase in the radioimmunoassayable titer of
AVP which occurred during A!! infusion would be accompa-
nied by parallel changes in renal water excretion. In these
studies, using a comparable range of doses of All as in the study
of Ramsay et al [31, Uosm did not rise, and plasma AVP
remained undetectable both during the i.v. and IC infusion of
All periods up to 40 minutes. These results, therefore, do not
provide evidence in support of a role for All in stimulating AVP
release in the water diuresing dog.
Shimizu, Share and Claybaugh [211, however, have suggested
a secondary role for angiotensin in stimulating AVP. These
authors suggested that angiotensin potentiated the osmotic
release of vasopressin. In our studies of hydropenic animals
with plasma osmolalities of 303 mOsm/kg H20 (Group 3) and
324 mOsm/kg H70 (Group 4), All failed to stimulate a rise in
plasma AVP despite causing blood pressure to increase 25 mm
Hg. Although AVP values in hydropenic dogs were consider-
ably lower than values reported by Ramsay et al allowed free
access to water (1.67 vs. 3.1 pg/mI) [3], they are not inconsistent
with other values reported in the literature in which AVP was
measured by radioimmunoassay in conscious dogs [30, 31].
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Moreover, Uosm not only failed to rise but actually decreased
significantly during the All infusion. Doses of All used in the
present study were as high as 20 ng/kg/min; this dose equals the
maximal dose used in the study of Ramsay et al [3]. If All does
not directly stimulate AVP release, the fall in Uosm was not an
unexpected response, since there is substantial information
indicating that the nonosmotic regulation of AVP is primarily
mediated by alterations in baroreceptor tone [1]. This pathway
would result in a suppression of AVP release with pressor doses
of All.
Another possibility was examined to explain the failure of All
to alter renal water excretion in our studies. All has been
shown to stimulate synthesis of renal PGs [22, 23] which would
then be expected to inhibit the in vivo action of AVP at the
collecting duct [8]. It is therefore conceivable that Uosm could
be unchanged despite a rise in circulating AVP. Prior support
for this construct had also been provided recently by Usberti et
al [27] in studies where aspirin had unmasked an inhibitory
effect of endogenous PGs on AVP actions. To test for the
possible role of PGs, studies were performed in conscious dogs
pretreated with indomethacin, a potent inhibitor of PG synthe-
sis. Basal AVP values in this indomethacin—treated group were
lower than in control hydropenic dogs. These results may
reflect an inhibition of AVP release by PG inhibition, a finding
with prior experimental support [32, 33]. In recent studies we
have noted a blunted AVP release in response to both osmotic
and non-osmotic stimuli [19]. In the present study, if angioten-
sin was stimulating AVP release, a rise in Uosm and plasma
AVP should have been observed in these indomethacin—treated
dogs. Again in these studies, however, All infusion failed to
stimulate AVP and Uosm declined, although not significantly.
The PRA values obtained in the present study exclude the
possibility that hydropenia caused a maximal rise in endoge-
nous All levels, thereby preventing any added effect from the
exogenous All infusions.
In summary, it is clear from the present group of studies that
neither IV nor IC infusions of All resulted in stimulation of
radioimmunoassayable AVP or altered renal water excretion in
the conscious dog. A possibility not excluded by these studies
is that All is capable of sustaining higher levels of AVP in
hydropenic conditions. Also, it should be noted that in all of the
in vivo studies performed to date, All infusions have increased
blood pressure, an effect which would oppose a direct stimula-
tory action of All on AVP release. Nonetheless, the net effect
in these studies is that renal water excretion is unchanged. Our
results do not support the contention that the renin—angiotensin
system plays a key role in the regulation of AVP release and
renal water excretion.
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